Small molecule · developed by Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals
EXS73565 is an orally administered agent studied in relapsed or refractory B-cell malignancies, including chronic lymphocytic leukemia/small lymphocytic lymphoma, follicular lymphoma, marginal zone lymphoma, mantle cell lymphoma, diffuse large B-cell lymphoma, and Waldenstrom's macroglobulinemia.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06980116 | Phase 1 | Relapsed or Refractory B-cell Malignancies | Recruiting | RXRX |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Diffuse-large B-cell Lymphoma (DLBCL)Follicular Lymphoma (FL)Mantle Cell Lymphoma (MCL)Marginal Zone Lymphoma (MZL)Relapsed or Refractory B-cell MalignanciesWaldenstrom's Macroglobulinemia (WM)
Updated Nov 1, 2026. Something wrong or missing? Report it on the RXRX page.
See RXRX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
RXRX catalysts and pipeline →